SCHEMBL17257561

SCHEMBL17257561

CC(=O)O/N=C(\C)c1sccc1C#N

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MAPT P10636 5/20 0.38
KDM4E B2RXH2 3/20 0.38
GAA P10253 2/20 0.38
RBBP9 O75884 4/20 0.36
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C19 P33261 2/20 0.36
CASP3 P42574 2/20 0.36
SENP8 Q96LD8 2/20 0.36
SENP7 Q9BQF6 2/20 0.36
SENP6 Q9GZR1 2/20 0.36
RECQL P46063 2/20 0.35
POLB P06746 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17257563 1.00 KMT2A (0.38) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL17256804 0.82 POLB (0.38) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL17256806 0.82 POLB (0.38) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL17256846 0.78 MEN1 (0.33) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL17256849 0.78 MEN1 (0.33) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL506452 0.78 KDM4E (0.41) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL12622649 0.75 POLB (0.52) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL17257663 0.74 CTDSP1 (0.39) KMT2AMEN1RAB9ASMN1; SMN2MAPT
SCHEMBL17257664 0.74 CTDSP1 (0.39) KMT2AMEN1RAB9ASMN1; SMN2MAPT
SCHEMBL17257375 0.73 ALDH1A1 (0.39) SMN1; SMN2MAPTGAAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US claimed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US claimed
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group BRIDGESTONE CORPORATION (JP) 2018-07-24 US disclosed
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP BRIDGESTONE CORPORATION (JP) 2015-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030083-B2 Polymers functionalized with protected oxime compounds containing a cyano group PAM, PPOX, MB KMT2A 2399/4885MEN1 3302/4885NPC1 4775/4885
US-20150329655-A1 POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS CONTAINING A CYANO GROUP PAM, PPOX, MB KMT2A 2399/4885MEN1 3302/4885NPC1 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.